Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
-
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
-
Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
-
Robbins LLP is Investigating Allegations that ImuunityBio, Inc. (IBRX) Misled Investors Regarding its Lead Product Candidate
-
Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
-
Robbins LLP is Investigating Allegations that REGENXBIO, Inc. (RGNX) Misled Investors Regarding the Viability of its Drug Candidate RGX-111
-
The Allegations: Robbins LLP is Investigating Allegations that uniQure (QURE) Misled Investors Regarding the Likelihood of FDA Approval of its Drug.
-
Daix (France), New York City (New York, Etats-Unis), le 28 novembre 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le...
-
Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...
-
Robbins LLP alerts investors to a class action involving MoonLake, alleging misleading statements on a drug candidate’s efficacy.